Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones
Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Dec 17, 2015
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
To evaluate the efficacy and safety of mini-PCNL versus standard-PCNL for the management of 20-40 mm size kidney stones.Investigators plan to do a multicenter, parallel, open-label randomized controlled trial (RCT). There are 20 hospitals included in this study, including The First Affiliated Hospital of Guangzhou Medical University, Baoshan No.2 People's Hospital, The second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Fujian Medical University, People's Hospital of Nanhai District, Yichang Yiling Hospital, Suzhou Municipal Hospital, Jining NO.1 People...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients consent for percutaneous renal stone removal
- • 2. Age 18 to 70 years
- • 3. Normal renal function
- • 4. ASA score Ⅰ and Ⅱ
- • 5. Renal stones 20-40mm
- Exclusion Criteria:
- • 1. Patients with solitary kidney.
- • 2. Uncorrected coagulopathy and active urinary tract infection (UTI)
- • 3. Morbid obese patients
- • 4. Patients who underwent transplant or urinary diversion.
- • 5. Congenital abnormalities.
About The First Affiliated Hospital Of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University is a leading clinical research institution located in Guangzhou, China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As a comprehensive teaching hospital, it integrates clinical practice, education, and research, fostering a multidisciplinary approach to healthcare. The hospital is equipped with state-of-the-art facilities and a team of experienced professionals dedicated to conducting high-quality clinical trials across various therapeutic areas. By leveraging its extensive expertise and resources, the First Affiliated Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Guohua Zeng, PH.D & MD
Principal Investigator
The First Affiliated Hospital of Guangzhou Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials